ARTICLE | Clinical News

Lyxumia lixisenatide: Phase III data

June 6, 2011 7:00 AM UTC

Top-line data from the double-blind, international Phase III GetGoal-L trial in 495 Type II diabetics inadequately controlled with basal insulin showed that once-daily 20 µg Lyxumia as an add-on to basal insulin with or without metformin met the primary endpoint of significantly reducing HbA1c from baseline to week 24 vs. placebo (p=0.0002). Lyxumia also met the secondary endpoints of significantly improving post-prandial plasma glucose after a test meal and of significantly reducing body weight vs. placebo (p<0.0001 for both). Additionally, Lyxumia did not significantly increase the risk of symptomatic hypoglycemia at week 24 vs. placebo (p=0.14). The most common adverse event was nausea. ...